Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus
Autore:
Ichimaru, N; Takahara, S; Kokado, Y; Wang, JD; Hatori, M; Kameoka, H; Inoue, T; Okuyama, A;
Indirizzi:
Osaka Univ, Sch Med, Dept Urol, Suita, Osaka 5650871, Japan Osaka Univ Suita Osaka Japan 5650871 pt Urol, Suita, Osaka 5650871, Japan Inoue Hosp, Dept Urol & Internal Med, Osaka 5640053, Japan Inoue Hosp Osaka Japan 5640053 Urol & Internal Med, Osaka 5640053, Japan
Titolo Testata:
ATHEROSCLEROSIS
fascicolo: 2, volume: 158, anno: 2001,
pagine: 417 - 423
SICI:
0021-9150(200110)158:2<417:CILMAE>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
REDUCTASE INHIBITORS; HYPERLIPIDEMIA; LOVASTATIN; THERAPY; HYPERCHOLESTEROLEMIA; RHABDOMYOLYSIS; HYPERTENSION; CHOLESTEROL; REJECTION; SURVIVAL;
Keywords:
renal transplantation; cyclosporine; tacrolimus; hyperlipidemia; hypercholesterolemia; hypertriglyceridemia;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Ichimaru, N Osaka Univ, Sch Med, Dept Urol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan Osaka Univ 2-2 Yamadaoka Suita Osaka Japan 5650871 0871, Japan
Citazione:
N. Ichimaru et al., "Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus", ATHEROSCLER, 158(2), 2001, pp. 417-423

Abstract

Hyperlipidemia is frequently developed following renal transplantation andresults in worsening of the patient's prognosis. In study 1, the effects of immuno suppress ants, cyclosporine (CsA) and tacrolimus on serum lipids were compared in-patients undergoing renal transplantation. The study included 32 cases of renal transplantation recipients who randomized to the CsA treatment group (15 patients) and the tacrolimus group (17 patients). Beforeand 1 month after the transplantation, we assessed the serum lipid levels,apolipoprotein levels, the concentrations of cholesterol in the respectivelipoprotein fractions and the enzyme activities related to lipid-metabolism. The serum lipid levels in both groups were significantly increased at 1 month after renal transplantation. In the CsA group, there were significantincreases in cholesterol contents in very-low-density lipoprotein (VLDL), LDL2 and HDL2 fractions, whereas, in the tacrolimus group, cholesterol content was increased in VLDL and HDL2 fractions. In study 2, 1 month after renal transplantation, 19 patients with hypercholesterolemia (total cholesterol (TC) > 200 mg/dl) and hypertriglyceridemia (triglyceride (TG) > 150 mg/dl) were treated with simvastatin 5-10 mg/day for 6 months. Sinavastatin treatment significantly decreased serum TC (240 +/- 29-200 +/- 22 mg/dl, P < 0.001), low-density lipoprotein cholesterol (LDL-C; 114 +/- 20-99 +/- 17 mg/dl, P < 0.05) and TG levels (217 +/- 103-130 +/- 38 mg/dl, P < 0.01). In addition, there were significant decreases in very-low-density lipoprotein cholesterol (VLDL-C; 53 +/- 20-34 +/- 15 mg/dl, P < 0.001). The Cmax and AUC of simvastatin were increased about eight-fold, when simvastatin was given in combination with CsA. In contrast, no significant changes in simvastatin levels were observed when combination with tacrolimus. Although simvastatinlevels were increased with CsA, there were no abnormal changes in renal and liver functions, creatinine phosphokinase (CPK) levels or in incidence ofadverse effects. (C) 2001 Elsevier Science Ireland Ltd, All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 12:25:24